Abstract
Introduction: The Centers for Medicare and Medicaid Services recently revised coverage of 18F-FDG PET/CT scans to only 3 posttherapy follow-ups for a tumor type per patient. The purpose of this study was to evaluate the added value of a fourth or subsequent follow-up PET/CT scans in clinical assessment and impact on management planning in patients with stomach cancer. Methods: This was a retrospective study in which a total of 4513 patients with biopsy-proven stomach cancer, who underwent PET/CT between 2010 and 2014 were identified. Among these, 553 patients had taken four or more follow-up PET/CT scans, for a total of 800 fourth and subsequent follow-up scans. Median follow-up from the fourth follow-up PET/CT scan was 23 months, ranging between 4˜54 months. The added value of each follow-up PET/CT scan result was determined by correlation with clinical assessment and consequent changes in treatment. Results: Of the 800 fourth and subsequent follow-up scans, 8 (1%) were interpreted as positive and 792 (99%) were interpreted as negative for local tumor recurrence or metastasis. PET/CT identified recurrent tumors in 4/700 (0.57%) of scan performed without clinical suspicion and ruled out disease in 96/100 (96%) of scan performed with prior clinical suspicion. Treatment changes were made after 5/800 (0.63%) PET/CT scans; new treatment was initiated after 3/800 (0.38%) scans and treatment was changed after 2/800 (0.25%) scans. Conclusion: Fourth and subsequent follow-up PET/CT scans performed after completion of primary treatment showed limited value in clinical assessment and management. However, they were helpful in excluding disease when performed in the presence of clinical suspicion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have